dapivirine ring previous safety experience mtn 020 training

19
Dapivirine Ring Previous Safety Experience MTN 020 Training

Upload: joseph-martin

Post on 04-Jan-2016

214 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Dapivirine Ring Previous Safety Experience MTN 020 Training

Dapivirine RingPrevious Safety Experience

MTN 020 Training

Page 2: Dapivirine Ring Previous Safety Experience MTN 020 Training

What do we know?

Side effects Pregnancy Resistance

Page 3: Dapivirine Ring Previous Safety Experience MTN 020 Training
Page 4: Dapivirine Ring Previous Safety Experience MTN 020 Training
Page 5: Dapivirine Ring Previous Safety Experience MTN 020 Training
Page 6: Dapivirine Ring Previous Safety Experience MTN 020 Training
Page 7: Dapivirine Ring Previous Safety Experience MTN 020 Training
Page 8: Dapivirine Ring Previous Safety Experience MTN 020 Training
Page 9: Dapivirine Ring Previous Safety Experience MTN 020 Training
Page 10: Dapivirine Ring Previous Safety Experience MTN 020 Training

Same rate as no ring groups in previous studies

Metrorrhagia is common

Page 11: Dapivirine Ring Previous Safety Experience MTN 020 Training
Page 12: Dapivirine Ring Previous Safety Experience MTN 020 Training
Page 13: Dapivirine Ring Previous Safety Experience MTN 020 Training
Page 14: Dapivirine Ring Previous Safety Experience MTN 020 Training
Page 15: Dapivirine Ring Previous Safety Experience MTN 020 Training

Pregnancy In rats, some effects on the developing fetus were observed

following oral administration at maternally toxic doses (80 mg/kg and 320 mg/kg) of dapivirine

No effects in rats at the maternally non-toxic dose of 20 mg/kg/day, or in rabbits at up to 90 mg/kg.

Insufficient information is currently available on dapivirine administration in pregnant women

Measures should be taken to avoid dapivirine exposure in women of childbearing potential or during pregnancy

Page 16: Dapivirine Ring Previous Safety Experience MTN 020 Training

Resistance In vitro studies of dapivirine have shown that NNRTI

resistance mutants can develop when virus is cultured in the setting of low concentrations of dapivirine

Major mutations for resistance are Y181C, K103N, L100I and E138K

Clinical significance of these in vitro studies not known

Page 17: Dapivirine Ring Previous Safety Experience MTN 020 Training

Conclusions

Safety: To date, ring is safe and well tolerated No treatment-related SAEs Related AEs were similar in dapivirine and placebo

rings groups in IPM studies, and consistent with background rates in the general population.

Page 18: Dapivirine Ring Previous Safety Experience MTN 020 Training

Acknowledgements

IPM colleagues

Page 19: Dapivirine Ring Previous Safety Experience MTN 020 Training

Questions?